Neonatal DiabetesMonogenic DiabetesMaturity Onset Diabetes of the Young
Investigational drug(s) / intervention(s)
No Interventions
No Interventions: No Interventions
Study summary
This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to:
Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution
Participants will:
* Enroll in the monogenic diabetes registry via mobile application or web-based platform
* Undergo molecular genetic testing to establish a definitive diagnosis
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age
2. Body mass index (BMI) at diagnosis 28 kg/m²
3. Negative glutamic acid decarboxylase antibody (GAD-Ab)
Exclusion Criteria:
1. Secondary diabetes
2. Active malignancy or history of malignant tumor within the past 5 years
Primary outcome measure(s)
Screened and confirmed monogenic diabetes — 6 months Screened and confirmed through genetic testing according to established diagnostic criteria for monogenic forms of diabetes (including MODY, neonatal diabetes, and other monogenic subtypes)
Trial sites (1)
Facility
City
Region
Status
Tianjin medical university general hospital
Tianjin
China
Recruiting
More Tianjin Medical University General Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.